LENZ Therapeutics (LENZ) Net Cash Flow (2020 - 2026)
LENZ Therapeutics (LENZ) reported Net Cash Flow of -$407000.0 for Q1 2026, down 114.11% year-over-year from $2.9 million in Q1 2025, and down 85.0% on a QoQ basis from -$220000.0 in Q4 2025.
LENZ Therapeutics (LENZ) has 7 years of Net Cash Flow data on file, last reported at -$407000.0 in Q1 2026.
- Quarterly Net Cash Flow fell 114.11% year-over-year to -$407000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (up 100.91% YoY) and the FY2025 annual result came in at $4.9 million, up 133.0% from the prior year.
- Net Cash Flow retreated to -$407000.0 in Q1 2026 per LENZ's latest filing, from -$220000.0 in the prior quarter.
- Across five years, Net Cash Flow topped out at $165.3 million in Q1 2024 and bottomed at -$191.9 million in Q1 2022.
- The 5-year median for Net Cash Flow is -$12.3 million (2025), against an average of -$20.5 million.
- The widest annual swing landed in 2022, when Net Cash Flow tumbled 246.27%; it then jumped 136.67% in 2023.
- Tracing LENZ's Net Cash Flow over 5 years: stood at -$8.7 million in 2022, then increased by 11.0% to -$7.7 million in 2023, then slumped by 170.99% to -$20.9 million in 2024, then soared by 98.95% to -$220000.0 in 2025, then sank by 85.0% to -$407000.0 in 2026.
- Per Business Quant, the three latest LENZ Net Cash Flow figures stand at -$407000.0 (Q1 2026), -$220000.0 (Q4 2025), and -$12.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.44 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 625.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 457.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -152.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 60.68 Mn |
| 10 | LENZ Therapeutics | 235.77 Mn | 235.77 Mn | 825,000.00 | -407,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -407,000.00 |
| Mar 31, 2026 | -407,000.00 |
| Dec 31, 2025 | -220,000.00 |
| Dec 31, 2025 | -220,000.00 |
| Sep 30, 2025 | -12.32 Mn |
| Sep 30, 2025 | -12.32 Mn |
| Jun 30, 2025 | 14.57 Mn |
| Jun 30, 2025 | 14.57 Mn |
| Mar 31, 2025 | 2.88 Mn |
| Mar 31, 2025 | 2.88 Mn |
| Dec 31, 2024 | -20.89 Mn |
| Dec 31, 2024 | -20.89 Mn |
| Sep 30, 2024 | -42.99 Mn |
| Sep 30, 2024 | -42.99 Mn |
| Jun 30, 2024 | -116.32 Mn |
| Jun 30, 2024 | -116.32 Mn |
| Mar 31, 2024 | 165.33 Mn |
| Mar 31, 2024 | 165.33 Mn |
| Dec 31, 2023 | -7.71 Mn |
| Dec 31, 2023 | -7.71 Mn |
| Sep 30, 2023 | -31.57 Mn |
| Sep 30, 2023 | -31.57 Mn |
| Jun 30, 2023 | -40.40 Mn |
| Jun 30, 2023 | -40.40 Mn |
| Mar 31, 2023 | 70.38 Mn |
| Mar 31, 2023 | 70.38 Mn |
| Dec 31, 2022 | -8.66 Mn |
| Dec 31, 2022 | -8.66 Mn |
| Sep 30, 2022 | -18.78 Mn |
| Sep 30, 2022 | -18.78 Mn |
| Jun 30, 2022 | -109.90 Mn |
| Jun 30, 2022 | -109.90 Mn |
| Mar 31, 2022 | -191.91 Mn |
| Mar 31, 2022 | -191.91 Mn |
| Dec 31, 2021 | -16.26 Mn |
| Dec 31, 2021 | -16.26 Mn |
| Sep 30, 2021 | 12.84 Mn |
| Sep 30, 2021 | 12.84 Mn |
| Jun 30, 2021 | 204.95 Mn |
| Jun 30, 2021 | 204.95 Mn |
| Mar 31, 2021 | 157.35 Mn |
| Mar 31, 2021 | 157.35 Mn |
| Dec 31, 2020 | 9.24 Mn |
| Dec 31, 2020 | 9.24 Mn |
| Sep 30, 2020 | -3.09 Mn |
| Sep 30, 2020 | -3.09 Mn |